Table 3 Univariate and multivariate analysis to test the association between GLS and different clinical parameters and medical treatments.
Variables | Univariate | Multivariablea | ||
|---|---|---|---|---|
Relative risk (95% CI) | P value | Relative risk (95% CI) | P value | |
Age | 0.18 | 0.007 | – | – |
Male | −0.10 | 0.142 | – | – |
cTnI | −0.56 | <0.0001 | −0.58 | <0.0001 |
NT-proBNP | −0.37 | <0.0001 | −0.37 | <0.0001 |
SpO2 | 0.43 | <0.0001 | 0.42 | <0.0001 |
hsCRP | −0.23 | 0.0002 | −0.20 | 0.006 |
ESR | −0.15 | 0.094 | −0.15 | 0.116 |
IL-6 | −0.23 | 0.001 | −0.21 | 0.003 |
IL-10 | −0.13 | 0.079 | −0.12 | 0.096 |
TNF-α | −0.19 | 0.006 | −0.16 | 0.022 |
Antiviral treatment | −0.71 | 0.723 | −0.73 | 0.344 |
Intravenous corticosteroid | −0.62 | 0.093 | −0.59 | 0.027 |
Oral corticosteroid | −0.47 | 0.521 | −0.48 | 0.346 |
Dopamine/norepinephrine | −0.16 | >0.999 | −63.3 | 1.000 |
